You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

908 Results
Document
New
Feb 2025
Document
New
Feb 2025
Document
New
Feb 2025
Les informations suivantes répondent à de nombreuses questions fréquemment posées par les médecins de première ligne au sujet du rapport d'activité...
Guidelines and Advice
Status: Current
Updated
Mar 2025
Guidelines and Advice
Updated
Mar 2025
Guidelines and Advice
Status: Current
Updated
Mar 2025
Drug
Other Name(s): Jakavi®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ruxolitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Document
New
Mar 2025

Pages